• Update of early phase clinical trials in cancer immunotherapy

• Lee Dae-Ho

• BMB Reports   2021  Volume.54  No.1 70 ~ 88

• Genome editing of immune cells using CRISPR/Cas9

• Kim Se-Gi

• Hupperetz Cedric, Lim Seong-Joon, Kim Chan-Hyuk

• BMB Reports   2021  Volume.54  No.1 59 ~ 69

• Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen recep...

• Kim Na-Young

• Lee Dong-Hee, Choi Woo-Seon, Yi Eun-Bi, Kim Hyo-Jeong, Kim Jung-Min, Jin Hyung-Seung, Kim ...

• BMB Reports   2021  Volume.54  No.1 44 ~ 58

• The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

• Kim Chae-Won

• Kim Kyun-Do, Lee Heung-Kyu

• BMB Reports   2021  Volume.54  No.1 31 ~ 43

• Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7

• Kim Ji-Hae

• Lee Kun-Joo, Lee Seung-Woo

• BMB Reports   2021  Volume.54  No.1 21 ~ 30

• Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activit...

• Yadollahi Pedram

• Jeon You-Kyoung, Ng Wooi Loon, Choi In-Hak

• BMB Reports   2021  Volume.54  No.1 12 ~ 20

• Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

• Jin Hyung-Seung

• Park Yoon

• BMB Reports   2021  Volume.54  No.1 2 ~ 11

• Cancer immunotherapy: special issue of BMB Reports in 2021

• Shin Eui-Cheol

• BMB Reports   2021  Volume.54  No.1 1 ~ 1